Clinical Trials Directory

Trials / Not Yet Recruiting

Not Yet RecruitingNCT07247630

Comparison of Permethrin-Based Treatment Strategies Against Scabies in Infants and Young Children

Status
Not Yet Recruiting
Phase
EARLY_Phase 1
Study type
Interventional
Enrollment
68 (estimated)
Sponsor
College of Physicians and Surgeons Pakistan · Academic / Other
Sex
All
Age
1 Month – 4 Years
Healthy volunteers
Not accepted

Summary

To compare the efficacy of different permethrin-based therapies for scabies infestations in infants and young children.

Detailed description

Globally, Scabies infects 300 million people each year and among children of developing countries, its prevalence is estimated to be about 5-10%.In Pakistan, Scabies accounts for 38% of dermatological diseases. Males are more prone to infestation than females, and early school- aged children are the most vulnerable as it is usually transmitted by prolonged skin-skin contact. It was more widespread in urban than in rural areas with a distinct seasonal pattern, with the biggest infestation occurring in the winter and the lowest in the summer with all risk factors accounting for 89% of the variation in its prevalence.The classic scabies symptoms include an erythematous papular eruption, burrows, and intense itching with a predilection for fingers, axilla, elbows, waist, belly, groin, genital area, etc. Several antiscabietic treatment options exist, including topically applied permethrin, benzyl benzoate (BB) and crotamiton, and oral ivermectin.5 Repeated administration of topical permethrin 5%, topical BB 10-25% or systemic ivermectin dosed at 200 μg/kg body weight is currently recommended as first-line treatment by the 2017 European guidelines for the management of scabies.Permethrin, a synthetic pyrethroid with scabicidal and ovicidal activity, disrupts the function of the voltage-gated sodium channels in the neuronal membrane of the mites, resulting in paralysis and death. Permethrin is highly effective against scabies and well- tolerated without major side-effects, as it is minimally absorbed through the skin and rapidly eliminated, thus exerting minimal systemic presence in humans.Hence, it is recommended as a first-line therapy for adults and children in many countries

Conditions

Interventions

TypeNameDescription
DRUGPermethrin 5%permethrin application

Timeline

Start date
2026-01-15
Primary completion
2026-03-15
Completion
2026-06-15
First posted
2025-11-25
Last updated
2026-02-03

Locations

1 site across 1 country: Pakistan

Source: ClinicalTrials.gov record NCT07247630. Inclusion in this directory is not an endorsement.